BioNexus Gene Lab Corp.
BGLC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.01 | 3.14 | -8.28 |
| FCF Yield | -49.33% | -21.60% | 0.30% | 0.00% |
| EV / EBITDA | -0.58 | -1.35 | -873.21 | 311.66 |
| Quality | ||||
| ROIC | -18.48% | -26.64% | -5.04% | 10.39% |
| Gross Margin | 13.56% | 13.61% | 11.52% | 16.42% |
| Cash Conversion Ratio | 1.40 | 0.67 | -1.55 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.53% | -9.91% | -1.37% | 372.15% |
| Free Cash Flow Growth | -24.83% | -496.18% | 8,195.57% | -95.42% |
| Safety | ||||
| Net Debt / EBITDA | 2.93 | 2.33 | 11.10 | -1.76 |
| Interest Coverage | -74.42 | -186.20 | -23.33 | 81.39 |
| Efficiency | ||||
| Inventory Turnover | 5.92 | 7.42 | 9.89 | 7.34 |
| Cash Conversion Cycle | 55.55 | 20.59 | 63.51 | 75.67 |